Induction of Plasmodium-Specific Immune Responses Using Liposome-Based Vaccines

Front Immunol. 2019 Feb 1;10:135. doi: 10.3389/fimmu.2019.00135. eCollection 2019.

Abstract

In the development of vaccines, the ability to initiate both innate and subsequent adaptive immune responses need to be considered. Live attenuated vaccines achieve this naturally, while inactivated and sub-unit vaccines generally require additional help provided through delivery systems and/or adjuvants. Liposomes present an attractive adjuvant/delivery system for antigens. Here, we review the key aspects of immunity against Plasmodium parasites, liposome design considerations and their current application in the development of a malaria vaccine.

Trial registration: ClinicalTrials.gov NCT02905019.

Keywords: Plasmodium; adjuvant; immunity; liposomes; malaria; vaccine.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Humans
  • Liposomes
  • Malaria Vaccines / administration & dosage*
  • Plasmodium / immunology*

Substances

  • Liposomes
  • Malaria Vaccines

Associated data

  • ClinicalTrials.gov/NCT02905019